CD244 Binding Vaccine for T Cell Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines often focus on humoral immunity and are ineffective against chronic infections and cancer, highlighting the need for vaccines that can induce strong T cell-mediated immune responses, particularly durable CD4+ and CD8+ T cell responses, to effectively clear pathogens or tumor cells.
Innovation Solution
Vaccine compositions comprising an agent that binds to CD244, an effective dose of an antigen, and an adjuvant that activates innate-like T cells, formulated as biodegradable microparticles to enhance T cell responses, including antigen-specific CD4+ and CD8+ T cell responses, and antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If vaccines focus on humoral immunity to generate neutralizing antibodies, then antibody production is improved, but T cell-mediated immune responses are insufficient
Solution Approach 1:
The vaccine composition merges multiple immune-stimulating components into a single formulation: CD244 binding agent (for T cell activation), antigen (for specific immune recognition), and adjuvant (for innate immune stimulation). This combination simultaneously promotes both humoral and cell-mediated immunity, resolving the contradiction between antibody production and T cell response effectiveness
Solution Approach 2:
The invention uses a composite vaccine composition containing distinct functional components (CD244 binding agent, antigen, adjuvant) that work synergistically. The CD244 binding agent specifically activates T cells while the adjuvant stimulates innate immunity, creating a composite immune response that overcomes the limitations of antibody-only vaccines against chronic infections and cancer
2Quantity of substance
If vaccines use traditional adjuvants, then humoral immunity is enhanced, but T cell responses are not sufficiently activated
Solution Approach 1:
The invention changes the key parameter of immune stimulation by introducing a CD244 binding agent that specifically targets T cell activation pathways. This parameter change shifts the immune response profile from primarily humoral to include robust T cell-mediated immunity, while maintaining adjuvant-driven antibody production
Solution Approach 2:
The CD244 binding agent acts as an intermediary that bridges the adjuvant and T cell components of the immune response. It mediates the activation of T cells by binding to CD244 receptors, thereby enhancing T cell responses without compromising the adjuvant's ability to stimulate antibody production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine compositions stimulate robust antigen-specific T cell responses and antibody production, promoting long-term immune protection against pathogens and tumors, as demonstrated by the induction of therapeutic and prophylactic effects in preclinical models.
Implementation Method 1
an agent that specifically binds to CD244
Implementation Method 2
an adjuvant, which adjuvant can be, without limitation, an activator of innate-like T cells
Implementation Method 3
formulated as biodegradable microparticles
Data Source
AI summary
Compositions and methods are provided relating to vaccine formulations comprising (i) an agent that specifically binds to CD244; (ii) an effective dose of an antigen; and (iii) an adjuvant, which adjuvant can be, without limitation, an activator of innate-like T cells.